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Phosphate prodrug strategies have been successfully used in 
the discovery of various nucleotide therapeutics that are 
nowadays used daily in the clinics to treat viral infections in 
particular hepatitis B and C (HBV and HCV, respectively) and 
HIV.[1] Over the last few years, the ‘ProTide’ technology -
pioneered by Chris McGuigan (Cardiff University, UK)- has 
emerged as a powerful strategy in the discovery of nucleotide 
therapeutics.[2] Indeed, this technology was used in the 
successful discovery and development of two FDA-approved 
‘ProTides’, Sovaldi and tenofovir alafenamide. The pipelines of 
several pharma and biotech companies seem to be stocked with 
a selection of ‘ProTides’, some of which are currently in Phase 
III clinical trials, while there is an increasing number of reports 
on ‘ProTides’ undergoing preclinical studies. Collectively, these 
reflect a ‘ProTides’ boom that could in the future be translated 
into the approval of more ‘ProTides’ to treat patients from viral 
infections and cancer.  
The in vivo activation of many antiviral and anticancer 
nucleosides involves phosphorylation into their active di- or 
triphosphate counterparts.[3] Among the three kinase-dependent 
phosphorylation steps required for the bioactivation of this class 
of therapeutics, the first phosphorylation step that converts 
nucleosides into their 5’-O-monophosphate derivatives is often 
found to be the rate-limiting step.[4] To overcome this inefficient 
activating metabolic step, numerous strategies that deliver 
nucleoside 5’-O-monophosphates into cells have been 
developed.[1] Nowadays, one of the most applied phosphate 
prodrug approaches is the ‘ProTide’ technology. The 
development[2] of this technology started by masking the 5’-O-
monophosphate groups of therapeutic nucleosides with simple 
dialkyl and then haloalkyl groups. However, these attempts did 
not lead to improved biological activity due most likely to the 
inability of these masking groups to be hydrolyzed in vivo to 
release the nucleoside monophosphate, which can subsequently 
be further phosphorylated to the active species. Next, McGuigan 
and co-workers synthesised alkyloxy and haloalkyl 
phosphoramidate prodrugs and these showed better activities 
than their parent nucleosides.[5] This was the first breakthrough 
in the development of the ‘ProTides’ and which provided 
evidence that masking of phosphate groups with biocleavable 
motifs may yield an effective prodrug system for the delivery of 
therapeutic nucleoside monophosphates. These initial studies 
identified L-alanine as a superior amino acid in the alkyloxy 
phosphoramidates, an observation that has informed recent 
drug discovery programs that yielded FDA-approved drugs.[5b] 
Encouraged by this, the phosphate group was masked with two 
amino acid esters. Back then, this was found not to be beneficial 
as the prodrugs were largely inactive. Diaryl phosphates were 
studied next and these showed very good activity. Hence, the 
McGuigan lab combined the amino acid ester from the alkyloxy 
and haloalkyl phosphoramidates and the aryl masking group to 
generate aryloxy triester phosphoramidates.[6] These were found 
to be superior in the delivery of therapeutic nucleoside 5’-O-
monophosphates. Since then, the masking of the phosphate 
group with an amino acid ester and an aryl motif, nowadays 
known as the ‘ProTide’ technology, has become an approved 
prodrug strategy in the discovery of nucleotide therapeutics. The 
mechanism by which the ‘ProTides’ are metabolized in vivo to 
release the nucleoside monophosphate is believed to proceed 
through the action of two enzymes; an esterase, e.g. cathepsin 
A,[7] and phosphoramidase-type enzyme, e.g. hint-1[8], as 
illustrated in Scheme 1.[2] 
Scheme 1. Postulated mechanism of the in vivo metabolism of the ‘ProTides’ 
to release nucleoside monophosphates. 
 
‘ProTides’ as clinical candidates and drugs 
To date, at least ten ‘ProTides’ have reached clinical trials and 
been investigated as treatments for viral infections and cancer 
[Figure 1]. The McGuigan lab discovered and developed the 
anti-HCV agent INX-189, a ‘ProTide’ of 6-O-methyl-2’-C-methyl 
guanosine (1).[9] This compound was at that time the most 
potent inhibitor of HCV replication in cell-based replication 
assays (EC50 = 0.01 µM; EC90 = 0.04 µM, CC50 = 7 µM). 
Critically, it generated significantly higher levels of the 6-O-
methyl-2’-C-methyl guanosine triphosphate than the parent 
nucleoside and had a half-life of over 24 hrs. Given the excellent 
pharmacokinetics (PK) and pharmacodynamics (PD) profiles of 
INX-189, it was chosen as a clinical candidate that was then 
developed by Inhibitex Inc.[10] Following successful early clinical 
results, INX-189 was acquired by Bristol-Myers Squibb (BMS) 
and studied in Phase III clinical trials in combination with 
daclatasvir, another anti-HCV experimental drug of BMS. 
However, cardiotoxicity was observed and further development 
was suspended.[11]  
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Other ‘ProTides’ for the treatment of hepatitis C, particularly PSI-
353661 (2)[12] and PSI-7977 (3)[13], proceeded to clinical 
evaluation.  PSI-353661 is a ‘ProTide’ of 6-O-methyl-2’-deoxy-2’-
fluoro-2’-C-methylguanosine while PSI-7977 is a ‘ProTide’ of 2’-
deoxy-2’-fluoro-2’-C-methyluridine. Both compounds showed 
potent anti-HCV activity through efficient delivery of the parent 
nucleosides 5’-O-monophosphates. As a result of the impressive 
early data from the clinical trials of these two agents, they were 
acquired by Gilead Sciences, Inc. Out of the two compounds, 
PSI-7977, which subsequently became GS-7977, completed 
successfully clinical evaluations and became known as 
Sofosbuvir (Sovaldi), the first ‘ProTide’ approved for clinical 
use against hepatitis C. 
GS-5734 (4)[14] is a C-nucleoside ‘ProTide’, which is currently 
undergoing Phase I clinical trials for the treatment of Ebola.[14] 
Preclinical data showed that GS-5734 exerted potent antiviral 
activity against variants of the Ebola virus. The ‘ProTide’ showed 
potent inhibition of EBOV replication (EC50 = 0.06 to 0.14 μM) 
while the parent C-nucleoside was not as effective (EC50 = 0.77 
to >20μM). Impressively, in rhesus monkeys infected with Ebola 
virus, once-daily intravenous administration of GS-5734 led to 
significant suppression of the Ebola virus replication and 100% 
protection of infected animals against lethal disease. GS-5734 
also showed promising inhibition of the replication of other 
pathogenic RNA viruses, e.g. arenaviruses, filoviruses, and 
coronaviruses, indicating the wide-spectrum of activity of this 
‘ProTide’. 
GS-7340 (5)[15], a ‘ProTide’ of the acyclic nucleoside 
phosphonate Tenofovir, of which the oral prodrug, Tenofovir 
disoproxil, is FDA-approved for HIV therapy, exhibited improved 
anti-HIV activity and better in vivo stability than Tenofovir. 
Impressively, the ‘ProTide’ GS-7340 generated 10- to 30-fold 
higher levels of Tenofovir and its phosphorylated metabolites 
following incubation of peripheral blood mononuclear cells 
compared with Tenofovir disoproxil and Tenofovir, 
respectively.[16] Although GS-7340 is similar to the FDA-
approved tenofovir disoproxil, it is more potent and thus in 
Phase III clinical studies therapeutic effects were achieved at 
lower doses and less incidence of side effects. In late 2015, GS-
7340, now known as tenofovir alafenamide, was approved in 
combination with other anti-HIV agents for the treatment of HIV-
1 infection. 
NUC-1031 (6)[17] is an anticancer ‘ProTide’ that was discovered 
by the McGuigan lab and is currently being developed by 
NuCana Biomed Ltd. It is a prodrug of the FDA-approved 
anticancer drug Gemcitabine (Gemzar). This compound 
overcame three resistance mechanisms that limit the efficacy of 
the parent nucleoside Gemcitabine. Results from phase I/II 
clinical trials showed that NUC-1031 was effective against a 
wide range of cancers and was well-tolerated by patients. 
Impressively, five out of 68 patients achieved tumor shrinkage of 
≥30% while an additional thirty-three patients had achieved 
stable disease. NuCana is also pushing forward the clinical 
development of NUC-3373[18], a ‘ProTide’ of 5-fluoro-2’-
deoxyuridine (FUDR) [structure not shown].  
At least a further four ‘ProTides’ were reported to have 
undergone clinical evaluation, i.e. Thymectacin (7) for cancer, 
Stampidine (8) and GS-9131 (9) for HIV; and GS-6620 (10) for 
hepatitis C.  
The plethora of ‘ProTides’ that have been, still undergoing or 
successfully completed clinical trials clearly highlights the 
effectiveness of this technology to deliver nucleotide 
therapeutics. Coupling this to the large number of ‘ProTides’ that 
are currently undergoing preclinical evaluation, it is safe to say 
that more ‘ProTides’ will progress into clinical studies increasing 
the chances of more ‘ProTides’ being approved in the future to 
treat viral infections and cancer. This has been made possible 
by the pioneering work of Prof. Chris McGuigan that started in 
the early 1990s and years later yielded the ‘ProTide’ technology 
as we know it today. Since its development, the ‘ProTide’ 
technology has been widely adopted and adapted by academic 
research groups, small and large pharmaceutical companies to 
discover new medicines that have already improved treatment 
outcomes and consequently the quality of life of many patients. 
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Figure 1. Chemical structures of a selection of ‘ProTides’ that have reached clinical trials and those that have been FDA-approved. 
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was invented by the McGuigan lab in the early 1990s, has 
proven to be effective in the discovery of nucleotide therapeutics. 
Impressively, it has already inspired the discovery of two FDA-
approved drugs with many more in (pre)clinical development.     
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